MPI increases its capital by 2,000 shares as a result of warrant exercise

2015-02-26

Hoersholm; February 26 2015 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of the exercise of warrants the share capital has been increased by DKK 2,000.

 The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 10.41 per share of nominally DKK 1.
Proceeds to the company are DKK 20,820.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2015. The new shares will be listed on First North after registration with the Danish Business Authority. MPI's current share capital amounts to DKK 1,097,770 and will after the capital increase be DKK 1,099,770. The capital increase is expected to be finalized shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 26 trials, where 22 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug.  Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute, Inc. advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.  

For further information please contact
Peter Buhl Jensen, CEO
E-mail: pbj@medical-prognosis.com
Cell Phone: (+45) 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark